The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin 4 receptor (hlL 4R). The formulations may contain in addition to an anti hlL 4R antibody at least one amino acid at least one sugar or at least one non ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
